Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin

Birthe Gade-Rasmussen; Sten Madsbad; Maria Saur Svane; Christoffer Martinussen; Torben Hansen

Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin

Translated title of the contribution: Successful treatment of KCNJ11 neonatal diabetes without insulin

Birthe Gade-Rasmussen, Sten Madsbad, Maria Saur Svane, Christoffer Martinussen, Torben Hansen

Department of Clinical Medicine

Abstract

In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).

Translated title of the contribution	Successful treatment of KCNJ11 neonatal diabetes without insulin
Original language	Danish
Article number	V08180547
Journal	Ugeskrift for Laeger
Volume	180
Issue number	46
Number of pages	2
ISSN	0041-5782
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/succesfuld-behandling-af-kcnj11-neonatal-diabetes-uden-insulin

Cite this

@article{c296441539db4aacb5b36d541686ae1a,

title = "Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin",

abstract = "In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).",

author = "Birthe Gade-Rasmussen and Sten Madsbad and Svane, {Maria Saur} and Christoffer Martinussen and Torben Hansen",

year = "2018",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "46",

}

TY - JOUR

T1 - Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin

AU - Gade-Rasmussen, Birthe

AU - Madsbad, Sten

AU - Svane, Maria Saur

AU - Martinussen, Christoffer

AU - Hansen, Torben

PY - 2018

Y1 - 2018

N2 - In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).

AB - In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).

M3 - Letter

C2 - 30417822

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 46

M1 - V08180547

ER -

Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this